266 related articles for article (PubMed ID: 12641614)
1. Urine biochemical markers of early renal dysfunction are associated with iron overload in beta-thalassaemia.
Koliakos G; Papachristou F; Koussi A; Perifanis V; Tsatra I; Souliou E; Athanasiou M
Clin Lab Haematol; 2003 Apr; 25(2):105-9. PubMed ID: 12641614
[TBL] [Abstract][Full Text] [Related]
2. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
Economou M; Printza N; Teli A; Tzimouli V; Tsatra I; Papachristou F; Athanassiou-Metaxa M
Acta Haematol; 2010; 123(3):148-52. PubMed ID: 20185899
[TBL] [Abstract][Full Text] [Related]
3. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Saliba AN; El Rassi F; Taher AT
Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
[TBL] [Abstract][Full Text] [Related]
4. Urinary iron excretion for evaluating iron chelation efficacy in children with thalassemia major.
Wahidiyat PA; Wijaya E; Soedjatmiko S; Timan IS; Berdoukas V; Yosia M
Blood Cells Mol Dis; 2019 Jul; 77():67-71. PubMed ID: 30978615
[TBL] [Abstract][Full Text] [Related]
5. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
[TBL] [Abstract][Full Text] [Related]
6. Combined iron chelation therapy.
Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW
Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
[TBL] [Abstract][Full Text] [Related]
7. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
Ha SY; Mok AS; Chu WC; Raskalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
Hemoglobin; 2009; 33(5):323-31. PubMed ID: 19814678
[TBL] [Abstract][Full Text] [Related]
8. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment.
Chirico V; Rigoli L; Lacquaniti A; Salpietro V; Piraino B; Amorini M; Salpietro C; Arrigo T
Eur J Haematol; 2015 May; 94(5):404-12. PubMed ID: 25200112
[TBL] [Abstract][Full Text] [Related]
9. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
[TBL] [Abstract][Full Text] [Related]
10. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
Farmaki K; Tzoumari I; Pappa C; Chouliaras G; Berdoukas V
Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
[TBL] [Abstract][Full Text] [Related]
11. [Program of hypertransfusion and chelation with desferrioxamine in 10 patients with thalassemia major].
Albo C; Cabrera J; Dios A; Castro M; Ares C; Constenla I; López D
Sangre (Barc); 1995 Dec; 40(6):441-5. PubMed ID: 8850225
[TBL] [Abstract][Full Text] [Related]
12. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
[TBL] [Abstract][Full Text] [Related]
13. Magnetic resonance screening of iron status in transfusion-dependent beta-thalassaemia patients.
Ooi GC; Khong PL; Chan GC; Chan KN; Chan KL; Lam W; Ng I; Ha SY
Br J Haematol; 2004 Feb; 124(3):385-90. PubMed ID: 14717788
[TBL] [Abstract][Full Text] [Related]
14. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
15. Renal iron deposition by magnetic resonance imaging in pediatric β-thalassemia major patients: Relation to renal biomarkers, total body iron and chelation therapy.
ElAlfy MS; Khalil Elsherif NH; Ebeid FSE; Ismail EAR; Ahmed KA; Darwish YW; Ibrahim AS; Elghamry IRF; Shokrey NA; Alajeil DN
Eur J Radiol; 2018 Jun; 103():65-70. PubMed ID: 29803388
[TBL] [Abstract][Full Text] [Related]
16. Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.
Dee CM; Cheuk DK; Ha SY; Chiang AK; Chan GC
Br J Haematol; 2014 Nov; 167(3):434-6. PubMed ID: 24989901
[No Abstract] [Full Text] [Related]
17. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F
Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
[TBL] [Abstract][Full Text] [Related]
19. Oral iron chelation therapy for thalassaemia: an uncertain scene.
Pippard MJ; Weatherall DJ
Br J Haematol; 2000 Oct; 111(1):2-5. PubMed ID: 11091177
[No Abstract] [Full Text] [Related]
20. β2-Microglobulin, Neutrophil Gelatinase-Associated Lipocalin, and Endocan Values in Evaluating Renal Functions in Patients with β-Thalassemia Major.
Cetinkaya PU; Azik FM; Karakus V; Huddam B; Yilmaz N
Hemoglobin; 2020 May; 44(3):147-152. PubMed ID: 32441176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]